Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and ...

By Padmanabhan Ananthan June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its ...

Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.

“We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer of Ascidian Therapeutics, told Fierce Biotech. That thinking has shaped how the ...

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney ...

The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without ...

Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments. Ascidian, a Boston-based biotechnology ...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...

Eli Lilly has struck a deal worth up to $1.9 billion with Boston biotech Ascidian Therapeutics to develop treatments for ...

The companies will use Ascidian Therapeutics' RNA exon-editing tech to develop treatments for undisclosed monogenic kidney diseases.